0001209191-22-061903.txt : 20221219 0001209191-22-061903.hdr.sgml : 20221219 20221219162125 ACCESSION NUMBER: 0001209191-22-061903 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221215 FILED AS OF DATE: 20221219 DATE AS OF CHANGE: 20221219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wagner Paul A. CENTRAL INDEX KEY: 0001612842 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38052 FILM NUMBER: 221471363 MAIL ADDRESS: STREET 1: C/O PFENEX INC. STREET 2: 10790 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Forte Biosciences, Inc. CENTRAL INDEX KEY: 0001419041 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261243872 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3060 PEGASUS PARK DRIVE STREET 2: BUILDING 6 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (310) 618-6994 MAIL ADDRESS: STREET 1: 3060 PEGASUS PARK DRIVE STREET 2: BUILDING 6 CITY: DALLAS STATE: TX ZIP: 75247 FORMER COMPANY: FORMER CONFORMED NAME: Tocagen Inc DATE OF NAME CHANGE: 20071120 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-15 0 0001419041 Forte Biosciences, Inc. FBRX 0001612842 Wagner Paul A. C/O FORTE BIOSCIENCES, INC. 3060 PEGASUS PARK DR., BLDG 6 DALLAS TX 75247 1 1 0 0 See Remarks Common Stock 2022-12-15 4 P 0 55976 1.0303 A 1335025 D Common Stock 2022-12-16 4 P 0 44024 1.0676 A 1379049 D Represents the weighted average share price of an aggregate total of 55,976 shares purchased in the price range of $1.00 to $1.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Represents the weighted average share price of an aggregate total of 44,024 shares purchased in the price range of $1.03 to $1.09 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. CEO, President, Secretary and Chair of the Board /s/ Paul A. Wagner, Ph.D 2022-12-19